GlaxoSmithKline

Wave Life Sciences Ltd. appoints Erik Ingelsson, MD, PhD, as Chief Scientific Officer to drive therapeutic portfolio strategy and enhance genetics/genomics capabilities.

The life sciences industry faces efficiency challenges driven by legislative changes and funding crunches, prompting a shift towards innovative, differentiated products. Outsourcing and tech-enabled solutions are crucial for biotechs and pharma companies to maximize value and speed up drug commercialization. Embracing AI and data analytics can revolutionize research and clinical trials, addressing data challenges and enhancing efficiency.

The article discusses the importance of summarizing content accurately and concisely, focusing on core information without explanatory sentences.

Sanofi in talks with Clayton Dubilier & Rice for sale of 50% stake in consumer health unit Opella, potentially worth €15 billion. Sale aims to focus resources on biopharmaceutical business, mirroring trends among big pharmas like Novartis, Pfizer, GSK, and Johnson & Johnson.

Competition authorities are expanding their review of pharmaceutical deals, focusing on whether existing tools for identifying and remedying competition issues are sufficient. The Multilateral Pharmaceutical Merger Task Force explores new enforcement approaches, considering factors like innovation effects, conglomerate effects, and coordinated effects. Authorities in regions like the EU, US, and APAC assess theories of harm, market definitions, and legal standards, with remedies often involving divestitures to ensure market competition.

AstraZeneca to pay $2B to CSPC for a cardiovascular drug, Astellas Pharma licenses gene therapy from AviadoBio, Merck partners with Mestag Therapeutics for fibrosis treatments, Insitro signs three agreements with Eli Lilly for metabolic diseases, MiNK Therapeutics and Autonomous Therapeutics collaborate on metastatic tumors, Bayer and MOMA Therapeutics partner in oncology, Wonderskin names 5W Public Relations as AOR, Eversana signs with Oracle Argus Cloud, Qinotto and Eli Lilly collaborate, Onspire Health acquires Aesthetic Brand Marketing, Reunion Neuroscience partners with Seleni Institute, Danco Laboratories to seek FDA approval for Mifeprex use in miscarriages, Exact Sciences' Cologuard Plus wins FDA approval, Boehringer Ingelheim's survodutide gets Breakthrough Therapy designation, Lunds & Byerlys recalls Lone Star Dip, Kezar Life Sciences' zetomipzomib development halted by FDA, Bayer's elinzanetant NDA accepted by FDA, Biogen's felzartamab gets Breakthrough Therapy Designation, Black Diamond Therapeutics to cut jobs, Upstream Bio targets $182M for IPO, City Therapeutics launches with $135M, Purespring Therapeutics raises $105M, Judo Bio launches with $100M, Orasis Pharmaceuticals raises $78M, CAMP4 Therapeutics targets $67M for IPO, Basecamp Research closes $60M Series B, Arda Therapeutics raises $43M Series A, Crinetics Pharmaceuticals announces public offering, GSK to pay $2.2B to settle Zantac lawsuits, Scholar Rock's SMA drug shows muscle function improvement, CDC to screen travelers due to Marburg virus outbreak in Rwanda, Ad Council, AMA, and CDC launch flu vaccination campaign, Sage Therapeutics' Sage-718 fails in Alzheimer's study, WeightWatchers adds GLP-1 obesity treatments, Gritstone Bio files for Chapter 11, BioPharmCatalyst launches AI-powered chatbot Aiden, Otsuka Precision Health and Amalgam Rx launch Alzheimer's app Elevmi, PatientPoint unveils interactive communication solution, Curia rebrands, Switzerland's COMCO terminates Novartis investigation, Bluebird Bio's Skysona linked to blood cancer in seven children, Solera Health rebrands, HearingLife launches pickleball sweepstakes, Alfasigma launches Morpho brand, Healthy Minds Innovations launches Our World Of Emotions campaign.

GSK's Arexvy RSV vaccine showed 62.9% efficacy against RSV-LRTD and 67.4% against severe RSV-LRTD over three seasons in adults aged 60+. The vaccine was also FDA-approved in June 2024 for adults aged 50-59 at increased risk of RSV-LRTD.

GSK’s Arexvy showed sustained protection over three RSV seasons in adults 60+; 62.9% efficacy against RSV-related lower respiratory tract disease and 67.4% against severe RSV-LRTD after one dose. Mild-to-moderate adverse events were common, and revaccination may be needed.

Baxter increases IV fluid allocations amid shortages; GSK to settle 80,000 Zantac lawsuits for up to $2.2B.